Compare BHM & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHM | ANL |
|---|---|---|
| Founded | 2022 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 52.0M |
| IPO Year | N/A | 2023 |
| Metric | BHM | ANL |
|---|---|---|
| Price | $8.58 | $1.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 4.6K | ★ 28.5K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | ★ 5.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,462,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.95 | N/A |
| 52 Week Low | $8.05 | $0.88 |
| 52 Week High | $14.81 | $2.99 |
| Indicator | BHM | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 55.10 |
| Support Level | $8.05 | $0.88 |
| Resistance Level | $8.88 | $1.59 |
| Average True Range (ATR) | 0.39 | 0.17 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 33.16 | 83.89 |
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The Company is an externally managed REIT managed and advised by Bluerock Homes Manager, LLC.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.